• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Inspection Summary Reports Call Out Data Integrity Problems

Clinical Inspection Summary Reports Call Out Data Integrity Problems

DataIntegrity-360x240.png
February 2, 2020
Leslie Ramsey

When a site undergoes an FDA inspection, just because its policies and procedures pass muster doesn’t mean the agency won’t ask for more proof of data reliability.

No Action Indicated (NAI) or Voluntary Action Indicated (VAI) classifications aren’t always the end of the enforcement activity. It’s the Clinical Inspection Summary (CIS) that determines whether the agency will take action on data integrity issues.

In addition to delivering a Form 483 listing compliance issues at the end of a site inspection, FDA field investigators prepare a CIS for review by the agency’s Center for Drug Evaluation and Research (CDER), closely examining any data issues found and how they affect the integrity of the trial’s findings. If the CIS suggests any concerns about the reliability or safety of a trial’s data, a site can find itself facing a number of corrective or preventive actions levied by CDER’s Office of Compliance (OC), according to former OC Director Cynthia Schnedar.

The agency “has been very clear that you could have an NAI or a VAI classification, and you could still get an active recommendation in the clinical inspection summary,” says Schnedar, executive vice president of regulatory compliance at Greenleaf Health.

Actions could range from requiring a repeat inspection or inspection of other trial sites, to requiring the trial to exclude questionable datasets or bringing in a third-party auditor. “They may have concerns that are so grave they think they need another set of eyes,” she says. “They may even ask you to conduct some additional studies or conduct additional analyses.”

Although not as severe as an Official Action Indicated (OAI) inspection classification, which can carry severe penalties, an active recommendation resulting from a CIS is a signal from the FDA that more needs to be done to ensure the reliability of the trial’s data. Between 2015 and 2017, 19 percent of CIS reports resulted in active recommendations.

To avoid active recommendations, Schnedar recommends informing the FDA as soon as an issue is discovered and asking the agency for help in resolving it. “FDA has been actively encouraging early engagement when you have a data integrity issue arise during your trial,” she says.

She points to one case in which a sponsor found an issue with their data — losing the audit trails due to a change of systems — and reported it to the agency. The FDA guided the sponsor through the process of fixing the problem, Schnedar says. “But they also mentioned that it would have been easier if the sponsor had disclosed earlier on when it discovered this problem, and that they probably could have addressed it more efficiently than they had to in the end.”

Rules for when to report data integrity issues are not clearly laid out by the agency, but she points out that involving the agency as you are working to resolve the problem helps ensure that you don’t affect or jeopardize the reliability of your data.

“So I think what’s important to keep in mind is that it’s always important that you maintain your trust in your relationship with FDA.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing